We use a patient-centric approach to identify and develop transformative medicines for the treatment of severe rare diseases. Our lead product candidate, apraglutide, is a next generation, long-acting synthetic GLP-2 analog which we are developing as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome.
May 25, 2021
VectivBio Appoints Omar Khwaja, M.D., Ph.D., as Chief Medical Officer
Christian Meyer, currently Chief Development Officer, to assume the newly created position of Chief Operating Officer Senior leadership appointments strengthen VectivBio as it continues development of apraglutide in short bowel syndrome and graft versus host disease, and expansion of its rare
April 13, 2021
VectivBio Announces Closing of $146.6 Million Initial Public Offering
BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a